Literature DB >> 1385156

CD59 molecule: a second ligand for CD2 in T cell adhesion.

M Deckert1, J Kubar, D Zoccola, G Bernard-Pomier, P Angelisova, V Horejsi, A Bernard.   

Abstract

The T cell surface molecule CD2 forms, with its counter-receptor CD58 (LFA-3), a powerful adhesion/activation pathway. There is some evidence that CD2 might bind more than a single ligand. Chinese hamster ovary cells (CHO) expressing human CD59 after cDNA transfection (CD59+CHO) form rosettes with human T cells; these rosettes are inhibited in a dose-dependent fashion by the CD59 monoclonal antibody (mAb) H19 and by the CD2 mAb O275 known to block natural rosettes, but not by the CD2R mAb D66, a poor rosette blocker. CD2+CHO transfectants form rosettes with human erythrocytes; these rosettes are inhibited by the CD59 mAb H19 in addition to CD2 mAb O275 and CD58 mAb; murine thymoma cells expressing human CD2 form rosettes with CD59+CHO cells that again are blocked by CD59 H19 and by CD2 O275 mAb. In a marked contrast with H19, two others CD59 mAb, YTH 53.1 and MEM 43, which react with a different epitope on CD59, led to a 50%-70% increase of the number of cells forming rosettes. In addition to rosette experiments, the binding of 125I-labeled CD59 molecules to CD2+CHO cells was specifically inhibited by unlabeled CD59 molecule and CD2 mAb. Furthermore, the binding of CD59 molecules to resting T cells induced expression of CD2R epitopes. These results directly show that CD2 binds CD59 and that subtle molecular changes occur upon binding.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1385156     DOI: 10.1002/eji.1830221128

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  25 in total

Review 1.  Characterization of the human antiporcine immune response: a prerequisite to xenotransplantation.

Authors:  A L Bothwell
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  T-cell stimulation through the T-cell receptor/CD3 complex regulates CD2 lateral mobility by a calcium/calmodulin-dependent mechanism.

Authors:  S Q Liu; D E Golan
Journal:  Biophys J       Date:  1999-03       Impact factor: 4.033

3.  CD2-mediated stimulation of the naive CD4+ T-cell subset promotes the development of skin-associated cutaneous lymphocyte antigen-positive memory cells.

Authors:  L Liu; A Foer; J Sesterhenn; U Reinhold
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

Review 4.  Membrane defence against complement lysis: the structure and biological properties of CD59.

Authors:  A Davies; P J Lachmann
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

5.  Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59.

Authors:  J Yu; T Caragine; S Chen; B P Morgan; A B Frey; S Tomlinson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

Review 6.  Mechanisms and assessment of lectin-mediated mitogenesis.

Authors:  D C Kilpatrick
Journal:  Mol Biotechnol       Date:  1999-02       Impact factor: 2.695

7.  Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59.

Authors:  D L Bodian; S J Davis; B P Morgan; N K Rushmere
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

8.  Glycosylphosphatidylinositol (GPI)-anchored surface antigens in the allogeneic activation of T cells.

Authors:  J Schubert; A Stroehmann; C Scholz; R E Schmidt
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

9.  Intracellular mediators regulate CD2 lateral diffusion and cytoplasmic Ca2+ mobilization upon CD2-mediated T cell activation.

Authors:  S J Liu; W C Hahn; B E Bierer; D E Golan
Journal:  Biophys J       Date:  1995-02       Impact factor: 4.033

10.  Absence of CD59 exacerbates systemic autoimmunity in MRL/lpr mice.

Authors:  Takashi Miwa; Lin Zhou; Michael A Maldonado; Michael P Madaio; Robert A Eisenberg; Wen-Chao Song
Journal:  J Immunol       Date:  2012-10-29       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.